Education
About Us
Working with TipRanks
Follow Us
Zoetis (ZTS)
NYSE:ZTS
ZTS Stock Chart & Stats
$127.30
$1.04(0.64%)
At close: 4:00 PM EST
$127.30
$1.04(0.64%)
Day’s Range― - ―
52-Week Range$115.25 - $177.00
Previous CloseN/A
Volume625.10K
Average Volume (3M)4.14M
Market Cap
$56.47B
Enterprise Value$62.18B
Total Cash (Recent Filing)$2.08B
Total Debt (Recent Filing)$7.27B
Price to Earnings (P/E)21.4
Beta0.56
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.69%
Share Statistics
EPS (TTM)1.37
Shares Outstanding440,693,200
10 Day Avg. Volume4,468,260
30 Day Avg. Volume4,138,689
Financial Highlights & Ratios
PEG Ratio3.88
Price to Book (P/B)15.51
Price to Sales (P/S)8.00
P/FCF Ratio32.20
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue6.62
Enterprise Value/Gross Profit9.37
Enterprise Value/Ebitda15.35
Forecast
1Y Price Target
$142.44Price Target Upside11.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Blockbuster Pipeline PotentialCompany highlights twelve potential blockbuster pipeline assets across established and emerging areas, signaling multiple sizable future revenue opportunities if clinical and regulatory milestones are met.
Commercial And Manufacturing ReadinessManagement states the commercial and manufacturing infrastructure is in place to scale global rollouts, supporting launches such as a long-acting monoclonal antibody for osteoarthritis pain in dogs that aims to increase convenience for pet owners.
R&D Approval CadenceManagement projects a steady stream of major approvals from the R&D pipeline, which could provide recurring new-product revenue and reduce reliance on legacy products.
Bears Say
Competitive Launch PressureNew product introductions from peers and initial promotional pricing in key growth segments could erode market share and compress pricing in core companion-animal categories.
Extended Development TimelinesExtended timelines for therapeutic programs in areas like oncology and cardiology push back anticipated revenue contributions and increase uncertainty around the timing of material pipeline-driven growth.
Librela Commercialization SetbacksCommercial execution issues and safety-related social media concerns have weighed on Librela sales, undermining the osteoarthritis pain franchise and pressuring near-term revenue expectations.
Zoetis News
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $115.25 and its highest was $177.00 in the past 12 months.
What is Zoetis’s market cap?
Zoetis’s market cap is $56.47B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Apr 30, 2026 which is in 77 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Feb 12, 2026. The company reported $1.37 earnings per share for the quarter, missing the consensus estimate of $1.402 by -$0.032.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.5 which represents an annual dividend yield of 1.69%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zoetis have?
Zoetis has 440,693,200 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.37 in its last earnings report, missing expectations of $1.402. Following the earnings report the stock price went down -13.779%.
Which hedge fund is a major shareholder of Zoetis?
Currently, no hedge funds are holding shares in ZTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zoetis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$142.44 (11.90% Upside)
$142.44 (11.90% Upside)
Blogger Sentiment
Bullish
ZTS Sentiment 95%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.66%
12-Months-Change
Fundamentals
Return on Equity
49.87%
Trailing 12-Months
Asset Growth
5.59%
Trailing 12-Months
Company Description
Zoetis
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
ZTS Company Deck
ZTS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects a fundamentally positive operational performance and financial discipline: solid organic revenue (6%), adjusted net income growth, margin expansion, strong franchises (Simparica, Diagnostics, Livestock), and active capital returns. However, material near-term headwinds remain—most notably weakness in the OA pain monoclonal antibody franchise, increased competitive promotional activity (especially in dermatology and parasiticides), U.S. clinic traffic sensitivity, and one-time international timing effects that complicate quarter-to-quarter comparability. Management provided prudent 2026 guidance that incorporates competition and timing adjustments while highlighting a robust pipeline and long-term growth drivers.View all ZTS earnings summariesZTS Revenue Breakdown
19.74% Vaccines
23.26% Parasiticides
17.88% Dermatology
11.88% Anti-infectives
7.11% Other pharmaceuticals
3.17% Medicated feed additives
4.17% Animal health diagnostics
2.73% Other non-pharmaceuticals
0.86% Contract manufacturing & human health
9.19% Pain and sedation
ZTS Stock 12 Month Forecast
Average Price Target
$142.44
▲(11.90% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
18.78% Mutual Funds
1.48% Other Institutional Investors
54.61% Public Companies and Individual Investors